The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2025

Filed:

Mar. 02, 2020
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Viktoria Gusarova, Pleasantville, NY (US);

Jesper Gromada, Scarsdale, NY (US);

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/40 (2005.12); A61K 9/00 (2005.12); C07K 16/22 (2005.12); A61K 39/00 (2005.12);
U.S. Cl.
CPC ...
C07K 16/40 (2012.12); A61K 9/0019 (2012.12); C07K 16/22 (2012.12); A61K 2039/505 (2012.12); A61K 2039/507 (2012.12); A61K 2039/545 (2012.12); C07K 2317/21 (2012.12); C07K 2317/56 (2012.12); C07K 2317/565 (2012.12); C07K 2317/76 (2012.12);
Abstract

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-PCSK9 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.


Find Patent Forward Citations

Loading…